Revelation Biosciences Stock Quote REVB - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.61

Bid

1.61

Ask

1.66

Volume

68,680

1.61 Day's Range 1.74

1.60 52 Week Range 28.20

Market Cap

2.743M

Previous Close

1.68

Open

1.64

Last Trade

100

1.61

Last Trade Time

14:19:46

Financial Volume

$ 113,222

VWAP

1.6485

Average Volume (3m)

710,567

Shares Outstanding

1,632,935

Dividend Yield

PE Ratio

-0.14

Earnings Per Share (EPS)

-0.07

Revenue

Net Profit

-120k

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Show more

Sector

Pharmaceutical Preparations

Industry

Blank Checks

Headquarters

Lewes, Delaware, USA

Founded

2022

Revelation Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker REVB. The last closing price for Revelation Biosciences was $1.68. Over the last year, Revelation Biosciences shares have traded in a share price range of $ 1.60 to $ 28.20.

Revelation Biosciences currently has 1,632,935 shares outstanding. The market capitalization of Revelation Biosciences is $2.74 million. Revelation Biosciences has a price to earnings ratio (PE ratio) of -0.14.

Form S-3 - Registration statement under Securities Act of 1933

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity- -Gemini was safe and well tolerated at pharmacologically active doses- -Phase 1...

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained...

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI...

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

– Oral presentation in addition to poster presentation announced January 30, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.25	-13.4408602151	1.86	2.14	1.6	231795	1.80395712	CS
4	-1.4	-46.511627907	3.01	3.8	1.6	2123511	2.36018835	CS
12	-0.59	-26.8181818182	2.2	3.8	1.6	710567	2.34908494	CS
26	-11.242	-87.4727668845	12.852	25.26	1.6	567156	4.27267302	CS
52	-22.663	-93.3671157253	24.273	28.2	1.6	313993	5.83444665	CS
156	-8797.39	-99.9817024662	8799	10237.5	1.6	1225274	931.770037	CS
260	-8797.39	-99.9817024662	8799	10237.5	1.6	1225274	931.770037	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 3.465 (403.05%)	129.98M
CMAXCareMax Inc	$ 5.2054 (229.46%)	87.17M
NUKKNukkleus Inc	$ 0.4819 (50.59%)	19.84M
LPSNLivePerson Inc	$ 1.305 (31.82%)	6.82M
SERVServe Robotics Inc	$ 9.8819 (30.89%)	128.73M
CGBSCrown LNG Holdings Ltd	$ 1.00 (-29.08%)	2.78M
LGCBLinkage Global Inc	$ 3.8048 (-27.04%)	150.01k
GSUNGolden Sun Health Technology Group Ltd	$ 5.0501 (-24.85%)	149.76k
IVPInspire Veterinary Partners Inc	$ 8.9105 (-24.17%)	707.36k
YYAIConnexa Sports Technologies Inc	$ 11.8358 (-22.18%)	61.67k
NVDANVIDIA Corporation	$ 123.61 (4.82%)	173.23M
SQQQProShares UltraPro Short QQQ	$ 8.08 (-4.49%)	147.37M
MIRAMIRA Pharmaceuticals Inc	$ 3.47 (403.77%)	130.04M
SERVServe Robotics Inc	$ 9.90 (31.13%)	128.74M
NCPLNetcapital Inc	$ 0.111 (6.73%)	116.68M